Coviccine Trivalent XBB.1.5 (recombinant COVID-19 trivalent (XBB+BA.5+Delta) protein vaccine (Sf9 Cell))
/ WestVac Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 25, 2024
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
(clinicaltrials.gov)
- P3 | N=4950 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
April 23, 2024
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
(clinicaltrials.gov)
- P3 | N=4950 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Trial completion date: Dec 2024 ➔ Jul 2025 | Initiation date: Oct 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2023 ➔ Jun 2024
Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
1 to 2
Of
2
Go to page
1